Medicare Enrolled
Dr. Neeraj Sharma, MD
Medical Oncology · Longview, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sharma from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sharma? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sharma
Dr. Neeraj Sharma is a medical oncology in Longview, TX, with 19 years in practice. Based on federal Medicare data, Dr. Sharma performed 126,783 Medicare services across 4,820 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sharma received a total of $3,969 from 30 pharmaceutical and/or device companies across 71 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sharma is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 6% volume in TX$ $3,969 industry payments
Medicare Practice Summary
Medicare Utilization ↗126,783
Medicare services
Top 6% in TX for medical oncology
4,820
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~6,673 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 35,700 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 20,480 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 17,300 | $42 | $137 |
| Paclitaxel chemotherapy injection | 10,234 | $0 | $8 |
| Iron sucrose injection (Venofer) | 8,900 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 6,400 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 6,194 | $0 | $3 |
| Dexamethasone injection (steroid) | 2,253 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,890 | $23 | $181 |
| Blood draw (venipuncture) | 1,847 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,693 | $8 | $36 |
| Injection, atropine sulfate, 0.01 mg | 1,480 | $0 | $1 |
| Comprehensive metabolic blood panel | 1,314 | $10 | $64 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,160 | $21 | $155 |
| Office visit, established patient (20-29 min) | 742 | $60 | $250 |
| Injection, granisetron hydrochloride, 100 mcg | 720 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 530 | $1 | $114 |
| Injection, fluorouracil, 500 mg | 513 | $2 | $13 |
| Injection, leucovorin calcium, per 50 mg | 499 | $3 | $25 |
| Injection, irinotecan, 20 mg | 482 | $2 | $210 |
| Office visit, established patient (30-39 min) | 459 | $89 | $368 |
| Administration of chemotherapy into vein, 1 hour or less | 383 | $97 | $707 |
| Injection, carboplatin, 50 mg | 320 | $2 | $300 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 283 | $22 | $157 |
| Ferritin level test (iron stores) | 268 | $13 | $60 |
| Iron level test | 268 | $6 | $27 |
| Iron binding capacity test | 268 | $9 | $35 |
| Injection of additional new drug or substance into vein | 247 | $12 | $108 |
| Lactate dehydrogenase (enzyme) level | 243 | $6 | $31 |
| Immunoglobulin level test | 228 | $9 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 180 | $54 | $211 |
| Injection, cisplatin, powder or solution, 10 mg | 154 | $2 | $94 |
| Drug injection, under skin or into muscle | 149 | $11 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 147 | $49 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 142 | $44 | $313 |
| Administration of chemotherapy into vein, each additional hour | 131 | $21 | $161 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 129 | $20 | $128 |
| Microscopic examination for white blood cells with manual cell count | 124 | $4 | $22 |
| Complete blood count (CBC), automated | 124 | $6 | $34 |
| Injection, zoledronic acid, 1 mg | 122 | $6 | $431 |
| Reticulated (young) platelet measurement | 108 | $35 | $143 |
| Injection, diphenhydramine hcl, up to 50 mg | 106 | $1 | $7 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 90 | $338 | $1,722 |
| Infusion, normal saline solution , 1000 cc | 84 | $2 | $19 |
| Carcinoembryonic antigen (cea) protein level | 83 | $19 | $99 |
| Hospital follow-up visit, moderate complexity | 83 | $59 | $247 |
| Thyroid stimulating hormone (TSH) test | 82 | $16 | $80 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 82 | $272 | $2,762 |
| Basic metabolic blood panel | 80 | $8 | $49 |
| PSA test (prostate cancer screening) | 70 | $18 | $94 |
| Injection, magnesium sulfate, per 500 mg | 70 | $1 | $6 |
| Unclassified drugs | 70 | $1 | $8 |
| Vitamin B-12 level test | 61 | $15 | $76 |
| Folic acid level test | 61 | $14 | $73 |
| New patient office visit (45-59 min) | 58 | $112 | $565 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 57 | $123 | $500 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 56 | $69 | $70 |
| Ct scan of chest with contrast | 52 | $44 | $821 |
| Irrigation of implanted venous access drug delivery device | 52 | $19 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 50 | $16 | $100 |
| CT scan of abdomen and pelvis with contrast | 48 | $159 | $1,067 |
| Injection of drug or substance into vein | 47 | $27 | $247 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 47 | $87 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 44 | $1,084 | $4,802 |
| Administration of additional new drug or substance into vein using push technique | 43 | $42 | $289 |
| Magnesium level test | 40 | $7 | $29 |
| New patient office visit, complex (60-74 min) | 38 | $160 | $709 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $23 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $15 | $94 |
| Infusion into a vein for hydration, each additional hour | 33 | $10 | $75 |
| Chest X-ray, 2 views | 31 | $15 | $61 |
| Drawing of blood for a medical problem | 31 | $58 | $264 |
| CT scan of chest, without contrast | 30 | $57 | $686 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $24 | $256 |
| Initial hospital admission, high complexity | 24 | $133 | $694 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 20 | $178 | $700 |
| Ct scan of abdomen and pelvis without contrast | 15 | $79 | $560 |
| Initial hospital admission, moderate complexity | 15 | $95 | $470 |
| Ct scan of soft tissue of neck with contrast | 13 | $73 | $658 |
| Stool analysis for blood to screen for colon tumors | 13 | $4 | $24 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.7% high complexity
64.1% medium
7.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,969
Total received (2018-2024)
Avg $662/year across 6 years
Top 50% in TX for medical oncology
30
Companies
71
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,614 (65.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,355 (34.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,037
2023$508
2022$88
2021$109
2019$1,214
2018$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$1,246
Secura Bio, Inc.
$1,200
Incyte Corporation
$177
GlaxoSmithKline, LLC.
$119
Novartis Pharmaceuticals Corporation
$102
Merck Sharp & Dohme LLC
$100
Karyopharm Therapeutics Inc.
$98
ADC Therapeutics America, Inc.
$96
Regeneron Healthcare Solutions, Inc.
$90
E.R. Squibb & Sons, L.L.C.
$83
Lilly USA, LLC
$80
Aveo Pharmaceuticals, Inc.
$77
Blueprint Medicines Corporation
$70
ABBVIE INC.
$65
AstraZeneca Pharmaceuticals LP
$54
SOBI, INC
$43
Seagen Inc.
$32
Bayer Healthcare Pharmaceuticals Inc.
$28
Geron Corporation
$26
GENZYME CORPORATION
$25
Eisai Inc.
$23
Genmab U.S., Inc.
$20
Jazz Pharmaceuticals Inc.
$20
JAZZ PHARMACEUTICALS INC.
$16
Immunocore Limited
$15
Sun Pharmaceutical Industries Inc.
$15
Bayer HealthCare Pharmaceuticals Inc.
$14
Alexion Pharmaceuticals, Inc.
$13
Seattle Genetics, Inc.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 66.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · CALQUENCE · DOPTELET · Doptelet · ELAHERE · ELIQUIS · FARYDAK · FOTIVDA · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · JAKAFI · JEMPERLI · KEYTRUDA · KIMMTRAK · KISQALI · LIBTAYO · LUTATHERA · Lenvima · MONJUVI · Nubeqa · OJJAARA · OPDIVO · Odomzo · PADCEV · PLUVICTO · RYTELO · SARCLISA · SHINGRIX · Stivarga · TASIGNA · Tivdak · ULTOMIRIS · VERZENIO · XALKORI · XPOVIO · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (66%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
3.2
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sharma is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and speaking/promotional industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sharma experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Sharma performed 35,700 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sharma receive payments from pharmaceutical companies?
Yes. Dr. Sharma received a total of $3,969 from 30 companies across 71 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sharma's costs compare to other medical oncologys in Longview?
Dr. Sharma's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sharma) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Longview
Browse medical oncologys in Longview ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Secura Bio, Inc. Payments to Doctors
See all physicians who received payments from Secura Bio, Inc..
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology